Abstract
It is not uncommon for anesthesiologists to encounter cancer patients who have received chemotherapy agents known to cause cardiovascular toxicities such as heart failure, systemic hypertension and thromboembolic events. Anthracyclines have been for several decades the most studied agents because of their known cardiovascular effects and relatively high incidence of heart failure. However, cancer patients are currently treated with newer chemotherapeutics such as imatinib, sunitinib, trastuzumab and bevacizumab that are also responsible of causing cardiovascular toxicities. The type of cardiotoxicity associated with these newer agents (type II cardiotoxicity) appears to be different in terms of pathogenesis to that caused by anthracyclines (type I cardiotoxicity). Thus, anesthesiologist needs to be aware of the clinical features of each type of cardiac toxicity. This review will summarize the current clinical evidence on cardiovascular toxicity induced by chemotherapeutic agents and will try to shed light on the current information regarding the perioperative management of patients with chemotherapy-induced cardiovascular toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 586-594 |
| Number of pages | 9 |
| Journal | Minerva Anestesiologica |
| Volume | 80 |
| Issue number | 5 |
| State | Published - May 2014 |
Keywords
- Anesthesiology
- Cardiotoxic agents
- Molecular targeted therapy
- Tyrosine-kinase inhibitor
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine